Cargando…

OMRT-12. Nanoparticle-based CRISPR-Cas9 delivery for anti-glioblastoma immunotherapy

Anti-glioblastoma GBM) immunotherapy poses a great challenge due to immunosuppressive brain tumor environments and the blood brain barrier (BBB). Programmed death ligand 1 (PD-L1) is an immune checkpoint that mediated the immune resistance. Inhibition of PD-L1 by antibodies was widely studied to tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aguilar, Rocio, Fierro, Javier, Perez, Joshua, Dou, Huanyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255442/ http://dx.doi.org/10.1093/noajnl/vdab070.036

Ejemplares similares

OTME-18. Targeted CRISPR/Cas9 gene-editing regulates the brain tumor environment
por: Perez, Joshua, et al.
Publicado: (2021)

NGMA-2. Dual sgRNA-directed PD-L1 knockout in human glioblastoma cells using the CRISPR/Cas9 system
por: Fierro, Javier, et al.
Publicado: (2021)

OMRT-11. The effect of microenvironment on glioblastoma stem cells therapeutic resistance
por: Turnsek, Tamara Lah, et al.
Publicado: (2021)

OMRT-13. Delivery of Ubidecarenone (BPM 31510) to mitochondria effectuates metabolic reprogramming and redox activated apoptosis in Glioblastoma
por: Sarangarajan, Rangaprasad, et al.
Publicado: (2021)

OMRT-1. Cannabidiol converts NFKB into a tumor-suppressor in glioblastoma with defined antioxidative properties
por: Volmar, Marie, et al.
Publicado: (2021)

OMRT-14. Small molecule circadian clock compounds exhibit potential as a novel therapy paradigm for glioblastoma
por: Chan, Priscilla, et al.
Publicado: (2021)

OMRT-8. Precision targeting of cellular pathways with complementary diagnostics
por: Siddaway, Robert, et al.
Publicado: (2021)

OMRT-2. Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma
por: Yekula, Anudeep, et al.
Publicado: (2021)

OMRT-6. Optimizing MDM2 inhibition for the treatment of high-grade glioma
por: Rendo, Veronica, et al.
Publicado: (2021)

OMRT-5. Therapy-induced reprogramming drives glioma vascular transdifferentiation and recurrence
por: Muthukrishnan, Sree Deepthi, et al.
Publicado: (2021)

OMRT-7. Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism
por: Khadka, Sunada
Publicado: (2021)

Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization
por: Fierro, Javier, et al.
Publicado: (2022)

OMRT-15. Multidisciplinary management of non-small cell lung cancer patients with leptomeningeal metastasis in the TKI era
por: Chen, Kuan-Yu, et al.
Publicado: (2021)

OMRT-3. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment
por: Varn, Frederick, et al.
Publicado: (2021)

OMRT-9. Effect of Pre-Operative Stereotactic Radiosurgery on Brain Metastasis: Analysis of DNA and RNA Genomic Profiles from Phase-II Clinical Trial NCT03398694
por: Shireman, Jack, et al.
Publicado: (2021)

Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing
por: Duan, Li, et al.
Publicado: (2021)

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
por: Zhang, Song, et al.
Publicado: (2021)

CRISPR-Cas9/Cas12a biotechnology and application in bacteria
por: Yao, Ruilian, et al.
Publicado: (2018)

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2023)

Recent Advances in CRISPR/Cas9 Delivery Strategies
por: Yip, Bon Ham
Publicado: (2020)

Editorial: Current approaches to CRISPR/Cas9 delivery
por: Uludağ, Hasan, et al.
Publicado: (2022)

Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme
por: Al-Sammarraie, Nadia, et al.
Publicado: (2021)

Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components
por: Kazemian, Pardis, et al.
Publicado: (2022)

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy
por: Ghaffari, Sasan, et al.
Publicado: (2021)

In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
por: Behr, Matthew, et al.
Publicado: (2021)

Advances in Chitosan-Based CRISPR/Cas9 Delivery Systems
por: Caprifico, Anna E., et al.
Publicado: (2022)

CRISPR-Cas9 delivery strategies with engineered extracellular vesicles
por: Lu, Yaoyao, et al.
Publicado: (2023)

Lipid nanoparticle-mediated CRISPR/Cas9 gene editing and metabolic engineering for anticancer immunotherapy
por: Ju, Hyemin, et al.
Publicado: (2022)

Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma
por: Liu, Xiao, et al.
Publicado: (2023)

QS3: CRISPR/Cas9 Editing of Autologous Dendritic Cells to Enhance Angiogenesis and Wound Healing
por: Henn, Dominic, et al.
Publicado: (2021)

CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy
por: Wang, Dan, et al.
Publicado: (2022)

Development of an in vivo cleavable donor plasmid for targeted transgene integration by CRISPR-Cas9 and CRISPR-Cas12a
por: Ishibashi, Riki, et al.
Publicado: (2022)

COT-12 Clinical feature of end-stage glioblastomas
por: Saito, Norihiko, et al.
Publicado: (2021)

CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials
por: Khalaf, Khalil, et al.
Publicado: (2020)

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems
por: Wang, Luyao, et al.
Publicado: (2022)

Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
por: Afolabi, Lukman O, et al.
Publicado: (2021)

CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy
por: Chen, Chen, et al.
Publicado: (2023)

Abstract 21: Identifying New Mutations Of Fgfr1a After CRISPR/Cas9 Genome Editing
por: Kelsey, Lauren, et al.
Publicado: (2017)

Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras(G12D) in pancreatic cancer
por: McAndrews, Kathleen M, et al.
Publicado: (2021)

VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9
por: Montagna, Claudia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5v0d8ke3t3bk5c9k5428fnogdv